A/Prof. Michael Kershaw
Honorary
The Sir Peter Maccallum Department of Oncology
147 Scholarly works
21 Projects
HIGHLIGHTS
2021
Journal article
A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer.
DOI: 10.1158/1078-0432.CCR-21-11412021
Journal article
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
DOI: 10.1136/jitc-2021-0025552021
Journal article
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
DOI: 10.1093/immadv/ltab0162021
Journal article
Generating CAR T cells from tumor-infiltrating lymphocytes.
DOI: 10.1177/251513552110171192018
Research Grant
IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER
2017
Research Grant
EXPLOITING AND DEFINING THE IMMUNE REGULATORY ACTIVITIES OF BET BROMODOMAIN INHIBITORS
2012
Research Grant
IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY
RECENT SCHOLARLY WORKS
2020
Journal article
Challenges and Opportunities for Effective Cancer Immunotherapies
DOI: 10.3390/cancers121131642020
Conference Proceedings
NOVEL COMBINATION IMMUNOTHERAPY FOR BOOSTING AND PRIMING IMMUNE RESPONSES IN PANCREATIC CANCER: STRONG ANTI-TUMOUR EFFECTS WITH INTERLEUKIN-15 AND CD40 AGONIST TREATMENT
DOI: 10.1136/jitc-2020-SITC2020.04532020
Conference Proceedings
EARLY-PHENOTYPE LEWIS Y CAR-T CELLS PERSIST BETTER IN VIVO AND INDUCE SOLID TUMOR REGRESSION IN COMBINATION WITH ANTI-PD1
DOI: 10.1136/jitc-2020-SITC2020.01262020
Journal article
Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses
DOI: 10.21037/jtd.2020.03.642020
Journal article
Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities
DOI: 10.21037/jtd.2020.03.342020
Journal article
Cross-talk between tumors at anatomically distinct sites
DOI: 10.1111/febs.15316
RECENT PROJECTS
2020
Research Grant
CAR T CELLS AND A GOOD “BEATING” FOR BREAST CANCERS
2018
Research Grant
USING LESSONS FROM TOXIC SHOCK SYNDROME TO ENHANCE BREAST CANCER IMMUNOTHERAPY